{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T21:10:15Z","timestamp":1716066615412},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s12072-013-9472-x","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T09:05:04Z","timestamp":1382432704000},"page":"1000-1009","source":"Crossref","is-referenced-by-count":2,"title":["The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (\u226580\u00a0% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial"],"prefix":"10.1007","volume":"7","author":[{"given":"Jung Hyun","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seok","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Kyon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Koo","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neung Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Woo","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,23]]},"reference":[{"key":"9472_CR1","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35\u2013S50","journal-title":"Gastroenterology"},{"key":"9472_CR2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958\u2013965","journal-title":"Lancet"},{"key":"9472_CR3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975\u2013982","journal-title":"N Engl J Med"},{"key":"9472_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","volume":"132","author":"ML Shiffman","year":"2007","unstructured":"Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103\u2013112","journal-title":"Gastroenterology"},{"key":"9472_CR5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2005.00697.x","volume":"13","author":"CD Howell","year":"2006","unstructured":"Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat 2006;13:371\u2013376","journal-title":"J Viral Hepat"},{"key":"9472_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.20984","volume":"43","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54\u201363","journal-title":"Hepatology"},{"key":"9472_CR7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1478-3231.2005.01196.x","volume":"26","author":"ML Yu","year":"2006","unstructured":"Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73\u201381","journal-title":"Liver Int"},{"key":"9472_CR8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/jhep.2002.36781","volume":"36","author":"AT Dev","year":"2002","unstructured":"Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002;36:1259\u20131265","journal-title":"Hepatology"},{"key":"9472_CR9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.amjmed.2004.02.043","volume":"117","author":"MJ Hepburn","year":"2004","unstructured":"Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163\u2013168","journal-title":"Am J Med"},{"key":"9472_CR10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2009.24.3.203","volume":"24","author":"JH Kwon","year":"2009","unstructured":"Kwon JH, Bae SH, Choi JY, Yoon SK, Byun KS, Paik SW, et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med 2009;24:203\u2013211","journal-title":"Korean J Intern Med"},{"key":"9472_CR11","first-page":"31","volume":"12","author":"H Lee","year":"2006","unstructured":"Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol 2006;12:31\u201340","journal-title":"Korean J Hepatol"},{"key":"9472_CR12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061\u20131069","journal-title":"Gastroenterology"},{"key":"9472_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399\u2013401","journal-title":"Nature"},{"key":"9472_CR14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105\u20131109","journal-title":"Nat Genet"},{"key":"9472_CR15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010;139:1181\u20131189","journal-title":"Gastroenterology"},{"key":"9472_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12072-012-9363-6","volume":"7","author":"M Nakagawa","year":"2013","unstructured":"Nakagawa M, Naoya Sakamoto N, Watanabe T, Nishimura-Sakurai Y, Onozuka I, Azuma S, et al. Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatol Int 2013;7:153\u2013161","journal-title":"Hepatol Int"},{"key":"9472_CR17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1478-3231.2011.02727.x","volume":"32","author":"A Tsubota","year":"2012","unstructured":"Tsubota A, Shimada N, Yoshizawa K, Furihata T, Agata R, Yumoto Y, et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int 2012;32:826\u2013836","journal-title":"Liver Int"},{"key":"9472_CR18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.510300319","volume":"30","author":"KR Reddy","year":"1999","unstructured":"Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30:787\u2013793","journal-title":"Hepatology"},{"key":"9472_CR19","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1572-0241.2007.01431.x","volume":"102","author":"S Missiha","year":"2007","unstructured":"Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007;102:2181\u20132188","journal-title":"Am J Gastroenterol"},{"key":"9472_CR20","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","volume":"350","author":"AJ Muir","year":"2004","unstructured":"Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265\u20132271","journal-title":"N Engl J Med"},{"key":"9472_CR21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2036.2012.05145.x","volume":"36","author":"AS Rangnekar","year":"2012","unstructured":"Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012;36:104\u2013114","journal-title":"Aliment Pharmacol Ther"},{"key":"9472_CR22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1440-1746.2011.06744.x","volume":"26","author":"DH Sinn","year":"2011","unstructured":"Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, Lee JH, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol 2011;26:1374\u20131379","journal-title":"J Gastroenterol Hepatol"},{"key":"9472_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jcv.2011.08.006","volume":"52","author":"K Lyoo","year":"2011","unstructured":"Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011;52:363\u2013366","journal-title":"J Clin Virol"},{"key":"9472_CR24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2011.03.029","volume":"56","author":"CF Huang","year":"2012","unstructured":"Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24\u00a0weeks peginterferon\/ribavirin. J Hepatol 2012;56:34\u201340","journal-title":"J Hepatol"},{"key":"9472_CR25","doi-asserted-by":"crossref","first-page":"e18322","DOI":"10.1371\/journal.pone.0018322","volume":"6","author":"CY Lin","year":"2011","unstructured":"Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011;6:e18322","journal-title":"PLoS One"},{"key":"9472_CR26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MCG.0b013e3182896abf","volume":"47","author":"YK Jung","year":"2013","unstructured":"Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol 2013;47:644\u2013650","journal-title":"J Clin Gastroenterol"},{"key":"9472_CR27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335\u20131374","journal-title":"Hepatology"},{"key":"9472_CR28","unstructured":"The national Center for Biotechnology Information. dbSNP. http\/\/www.ncbi.nlm.nih.gov\/projects\/SNP\/ . Accessed 30 Nov 2012"},{"key":"9472_CR29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","volume":"464","author":"J Fellay","year":"2010","unstructured":"Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405\u2013408","journal-title":"Nature"},{"key":"9472_CR30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3851\/IMP2026","volume":"17","author":"CH Liu","year":"2012","unstructured":"Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, et al. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 2012;17:477\u2013484","journal-title":"Antivir Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-013-9472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9472-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T20:34:04Z","timestamp":1716064444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-013-9472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["9472"],"URL":"https:\/\/doi.org\/10.1007\/s12072-013-9472-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}